Increased demand for aseptic filling sees Cytiva boost manufacturing capacity in Vancouver

By Jane Byrne contact

- Last updated on GMT

Robotic aseptic filling workcells © Cytiva
Robotic aseptic filling workcells © Cytiva

Related tags: aseptic filling, Vials, syringes, Cytiva

This week saw Cytiva open a new 126 200 ft2 (11,724 m2) site in the greater Vancouver area, Canada.

It means manufacturing capacity of aseptic filling machinery is expanded by over 200%.

Cytiva said the machines, known as workcells, provide gloveless, robotic aseptic filling capability for final drug product into vials, syringes, and cartridges. “Robotic aseptic filling workcells reduce risk and increase flexibility in pharmaceutical manufacturing.”

The site will serve as a Center of Excellence for Cytiva’s aseptic filling business, housing R&D and service. “Manufacturing will begin on the first workcell to be built at the newly opened site in September, with production to be fully transferred over to the new site by the end of this year.” 

cytiva
'New site will allow 200% greater production capacity' © Cytiva

Olivier Loeillot, vice president, bioprocess, Cytiva, told us the aseptic filling business has grown rapidly since the company acquired it from Vanrx Pharmasystems in February 2021.

“The current location became too small to house our people as well as meet increased production from customer demand, so a new, larger space was needed.

“This expansion reflects the growing industry acceptance of what is a fundamentally different technology than what came before. It gives us plenty of room to meet the steadily growing demand for idea to injection solutions for our customers.”

Energy conservation 

The facility, which is located in Burnaby, British Columbia, is also heavily focused on ensuring sustainable production, said Cytiva.

All lighting in the building is LED and tied to motion sensors to conserve energy. There is a comprehensive recycling and waste management program and six electric car charging stations, with capacity for additional stations as needed.”

The new plant also has 20 build bays outfitted with customizable electrical and mechanical infrastructure changeable for shifting production needs; 40-foot warehouse height to accommodate incoming materials and outgoing finished goods; and special air handling technology for better air quality in assembly areas, including louvres that can open the manufacturing space to fresh air, said the group. 

The facility will house around 200 employees by the end of 2022, with room for future expansion.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Related suppliers

Follow us

Products

View more

Webinars